EU urges member states to boost access to orphan drugs - update
This article was originally published in Scrip
The European Commissionhas set out a strategy for improving the recognition, diagnosis and treatment of rare diseases. The proposals include speeding up patient access to orphan drugs by better assessing their value for pricing and reimbursement purposes, and encouraging more research into new therapies.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.